(Q33335129)

25 July 2017

1 reference

title

Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance (English)

1 reference

25 July 2017

1 reference

R Paul

1

1 reference

PubMed ID

11085345

25 July 2017

J Breul

series ordinal

2

1 reference

25 July 2017

1 November 2000

1 reference

25 July 2017

1 reference

25 July 2017

23

1 reference

25 July 2017

381-390

1 reference

25 July 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200023050-00003

25 July 2017

0 references

cites work

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade

1 reference

12 December 2020

Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone

1 reference

12 December 2020

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

12 December 2020

Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance

1 reference

12 December 2020

Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma

1 reference

12 December 2020

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

1 reference

12 December 2020

[The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens]

1 reference

12 December 2020

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

1 reference

12 December 2020

Antiandrogen withdrawal syndrome with cyproterone acetate

1 reference

12 December 2020

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

12 December 2020

Secondary hormonal manipulations in hormone refractory prostate cancer

1 reference

12 December 2020

Treatment of advanced prostatic cancer.

1 reference

12 December 2020

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

12 December 2020

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

12 December 2020

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

12 December 2020

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal

1 reference

12 December 2020

[Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape]

1 reference

12 December 2020

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

12 December 2020

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

1 reference

12 December 2020

Antiandrogen withdrawal syndrome with nilutamide

1 reference

12 December 2020

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

1 reference

12 December 2020

Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer

1 reference

12 December 2020

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

1 reference

12 December 2020

Androgen receptor gene mutations in human prostate cancer

1 reference

12 December 2020

Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens

1 reference

12 December 2020

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report

1 reference

12 December 2020

Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy

1 reference

12 December 2020

Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate

1 reference

12 December 2020

Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer

1 reference

12 December 2020

Purification of a human prostate specific antigen

1 reference

12 December 2020

Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate

1 reference

12 December 2020

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy

1 reference

12 December 2020

Response of carcinoma of the prostate to withdrawal of flutamide

1 reference

12 December 2020

Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer

1 reference

12 December 2020

Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer

1 reference

12 December 2020

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers

1 reference

12 December 2020

Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome

1 reference

12 December 2020

Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal

1 reference

12 December 2020

Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy

1 reference

12 December 2020

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

12 December 2020

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

1 reference

12 December 2020

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

1 reference

12 December 2020

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

12 December 2020

Withdrawal phenomenon with the antiandrogen casodex

1 reference

12 December 2020

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol

1 reference

12 December 2020

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

1 reference

12 December 2020

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome

1 reference

12 December 2020

10.2165/00002018-200023050-00003

Identifiers

DOI

1 reference

PubMed ID

11085345

Dimensions Publication ID

25 July 2017

0 references

1 reference

PubMed ID

11085345